P1333: Trajectory analyses to optimise third booster COVID-19 vaccination in patients with Inflammatory Bowel Disease: final analyses of the J-COMBAT trialECCO'25Year: 2025
Authors: WatanabeMD- PhD- FACG- FJGES, K.(1)*;Nojima, M.(2);Nakase, H.(3);Tamano, S.(2);Matsuura, M.(4);Aoyama, N.(5);Kobayashi, T.(6);Sakuraba, H.(7);Nishishita, M.(8);Yokoyama, K.(9);Esaki, M.(10);Hirai, F.(11);Nagahori, M.(12);Nanjo, S.(13);Omori, T.(14);Tanida, S.(15);Yokoyama, Y.(3);Moriya, K.(16);Maemoto, A.(17);Handa, O.(18);Ohmiya, N.(19);Shinzaki, S.(20);Kato, S.(21);Tanaka, H.(22);Uraoka, T.(23);Takatsu, N.(24);Suzuki, H.(25);Nishida, A.(26);Umeno, J.(27);Mishima, Y.(28);Tsuchida, K.(29);Fujiya, M.(30);Hiraoka, S.(31);Okabe, M.(32);Toyonaga, T.(33);Ando, A.(26);Hisamatsu, T.(4);
(1)Toyama University, Internal Medicine for Inflammatory Bowel Disease, Toyama, Japan;(2)The University of Tokyo, Center for Translational Research- The Institute of Medical Science Hospital, Tokyo, Japan;(3)Sapporo Medical University School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan;(4)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Mikata, Japan;(5)Aoyama Clinic, Gastroenterology, Kobe, Japan;(6)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment- Department of Gastroenterology, Tokyo, Japan;(7)Hirosaki University Graduate School of Medicine, Department of Gastroenterology and Hematology, Hirosaki, Japan;(8)Nishishita Gastrointestinal Hospital, Gastroenterology, Osaka, Japan;(9)Kitasato University School of Medicine, Department of Gastroenterology, Sagamihara, Japan;(10)Saga University, Division of Gastroenterology- Department of Internal Medicine, Saga, Japan;(11)Fukuoka University Faculty of Medicine, Department of Gastroenterology and Medicine, Fukuoka, Japan;(12)Institute of Science Tokyo Hospital, Clinical Research Center, Tokyo, Japan;(13)University of Toyama, Third Department of Internal Medicine, Toyama, Japan;(14)Tokyo Women's Medical University, Institute of Gastroenterology, Tokyo, Japan;(15)Nagoya City University Graduate School of Medical Sciences, Education and Research Center for Community Medicine, Nagoya, Japan;(16)Nara Medical University, Department of Gastroenterology, Nara, Japan;(17)Sapporo Higashi Tokushukai Hospital, IBD Center, Sapporo, Japan;(18)Kawasaki Medical School, Department of Internal Medicine- Division of Gastroenterology, Kurashiki, Japan;(19)Fujita Health University School of Medicine, Department of Advanced Endoscopy, Toyoake, Japan;(20)Osaka University Graduate School of Medicine- Hyogo Medical University, Department of Gastroenterology, Osaka, Japan;(21)Saitama Medical Center- Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe, Japan;(22)Sapporo IBD Clinic, Gastroenterology, Sapporo, Japan;(23)Gunma University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Maebashi, Japan;(24)Fukuoka University Chikushi Hospital, Inflammatory Bowel Disease Center, Fukuoka, Japan;(25)University of Tsukuba, Department of Gastroenterology, Tsukuba, Japan;(26)Shiga University of Medical Science, Department of Medicine, Otsu, Japan;(27)Graduate School of Medical Sciences- Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan;(28)Shimane University Faculty of Medicine, Department of Internal Medicine II, Matsue, Japan;(29)Nagoya City University West Medical Center, Gastroenterology, Nagoya, Japan;(30)Asahikawa Medical University, Gastroenterology and Endoscopy- Division of Metabolism and Biosystemic Science- Gastroenterology- and Hematology/Oncology- Department of Medicine, Asahikawa, Japan;(31)Okayama University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Okayama, Japan;(32)Graduate School of Medicine- Kyoto University, Department of Gastroenterology and Hepatology, Kyoto, Japan;(33)The Jikei University School of Medicine, Department of Gastroenterology and Hepatology- Division of Internal Medicine, Tokyo, Japan; on behalf of the J-COMBAT study group
1. Nakase H, Hayashi Y, Yokoyama Y, et al. Final Analysis of COVID-19 Patients With Inflammatory Bowel Disease in Japan (J-COSMOS): A Multicenter Registry Cohort Study.Gastro Hep Adv. 2023;2(8):1056-1065.
2. Nakase H, Wagatsuma K, Nojima M, et al. Anxiety and behavioral changes in Japanese patients with inflammatory bowel disease due to COVID-19 pandemic: a national survey. J Gastroenterol. 2023;58(3):205-216.
3. Watanabe K, Nojima M, Nakase H, et al. Trajectory analyses to identify persistently low responders to COVID-19 vaccination in patients with inflammatory bowel disease: a prospective multicentre controlled study, J-COMBAT. J Gastroenterol. 2023;58(10):1015-1029.
P1334: Acute Severe Ulcerative Colitis: When Epstein-Barr Virus Joins Forces with Clostridioides difficileECCO'25Year: 2025
Authors: Côrte-Real, F.(1)*;Rego, A.C.(1);Silva, A.R.(1);Flor de Lima, M.(1);Almeida, M.(2);Pereira, J.R.(1);Paz, N.(1);Carneiro, V.(3);Nunes, N.(1);Duarte, M.A.(1);
(1)Hospital do Divino Espírito Santo de Ponta Delgada, Gastroenterology, Ponta Delgada, Portugal;(2)Hospital do Divino Espírito Santo de Ponta Delgada, General Surgery, Ponta Delgada, Portugal;(3)Hospital do Divino Espírito Santo de Ponta Delgada, Anatomical Pathology, Ponta Delgada, Portugal;
1 - Afzal M, Nigam GB. EBV colitis with ulcerative colitis: A double whammy. BMJ Case Rep. 2018;2018:1–3.
2 - Zhang H, Zhao S, Cao Z. Impact of Epstein–Barr virus infection in patients with inflammatory bowel disease. Front Immunol. 2022;13(October):1–15.
3 - Spinelli A, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. J Crohn’s Colitis. 2022;16(2):179–89.
P1335: Dietary Carnosic Acid Eases Colitis by Activating NRF2 Signal via Regulating Gut Microbiota and MetabolitesECCO'25Year: 2025
Authors: Xiaohan, W.(1)*;feng, T.(1);
(1)Department of Gastroenterology, Shengjing Hospital of China Medical University, shenyang, China;
[1] Loussouarn M, Krieger-Liszkay A, Svilar L, et al. Carnosic Acid and Carnosol, Two Major Antioxidants of Rosemary, Act through Different Mechanisms[J]. Plant Physiol, 2017,175(3):1381-1394.
[2] Bahri S, Jameleddine S, Shlyonsky V. Relevance of carnosic acid to the treatment of several health disorders: Molecular targets and mechanisms[J]. Biomed Pharmacother, 2016,84:569-582.
[3] Satoh T, Trudler D, Oh C K, et al. Potential Therapeutic Use of the Rosemary Diterpene Carnosic Acid for Alzheimer's Disease, Parkinson's Disease, and Long-COVID through NRF2 Activation to Counteract the NLRP3 Inflammasome[J]. Antioxidants (Basel), 2022,11(1).
[4] Li X, Zhao L, Han J J, et al. Carnosol Modulates Th17 Cell Differentiation and Microglial Switch in Experimental Autoimmune Encephalomyelitis[J]. Front Immunol, 2018,9:1807.
[5] Veenstra J P, Vemu B, Tocmo R, et al. Pharmacokinetic Analysis of Carnosic Acid and Carnosol in Standardized Rosemary Extract and the Effect on the Disease Activity Index of DSS-Induced Colitis[J]. Nutrients, 2021,13(3).
[6] David L A, Maurice C F, Carmody R N, et al. Diet rapidly and reproducibly alters the human gut microbiome[J]. Nature, 2014,505(7484):559-563.
[7] Guo C, Wang Y, Zhang S, et al. Crataegus pinnatifida polysaccharide alleviates colitis via modulation of gut microbiota and SCFAs metabolism[J]. Int J Biol Macromol, 2021,181:357-368.
[8] Glassner K L, Abraham B P, Quigley E. The microbiome and inflammatory bowel disease[J]. J Allergy Clin Immunol, 2020,145(1):16-27.
[9] He X, Zhang M, Li S T, et al. Alteration of gut microbiota in high-fat diet-induced obese mice using carnosic acid from rosemary[J]. Food Sci Nutr, 2022,10(7):2325-2332. [10] Ou J, Huang J, Zhao D, et al. Protective effect of rosmarinic acid and carnosic acid against streptozotocin-induced oxidation, glycation, inflammation and microbiota imbalance in diabetic rats[J]. Food Funct, 2018,9(2):851-860.
[11] Li D, Wang P, Wang P, et al. Targeting the gut microbiota by dietary nutrients: A new avenue for human health[J]. Crit Rev Food Sci Nutr, 2019,59(2):181-195.
[12] Welihinda A A, Kaur M, Greene K, et al. The adenosine metabolite inosine is a functional agonist of the adenosine A2A receptor with a unique signaling bias[J]. Cell Signal, 2016,28(6):552-560.
[13] Mager L F, Burkhard R, Pett N, et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy[J]. Science, 2020,369(6510):1481-1489.
[14] Rahimian R, Fakhfouri G, Daneshmand A, et al. Adenosine A2A receptors and uric acid mediate protective effects of inosine against TNBS-induced colitis in rats[J]. Eur J Pharmacol, 2010,649(1-3):376-381.
[15] Mabley J G, Pacher P, Liaudet L, et al. Inosine reduces inflammation and improves survival in a murine model of colitis[J]. Am J Physiol Gastrointest Liver Physiol, 2003,284(1):G138-G144.
[16] Peng S, Shen L, Yu X, et al. The role of Nrf2 in the pathogenesis and treatment of ulcerative colitis[J]. Front Immunol, 2023,14:1200111.
[17] Singh R, Chandrashekharappa S, Bodduluri S R, et al. Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway[J]. Nat Commun, 2019,10(1):89.
[18] Abdelkader N F, Ibrahim S M, Moustafa P E, et al. Inosine mitigated diabetic peripheral neuropathy via modulating GLO1/AGEs/RAGE/NF-kappaB/Nrf2 and TGF-beta/PKC/TRPV1 signaling pathways[J]. Biomed Pharmacother, 2022,145:112395.
P1336: Gut mycobiome in the NORDTREAT cohort of new onset inflammatory bowel disease.ECCO'25Year: 2025
Authors: Füchtbauer, J.D.(1,2,3)*;Brovkina, O.(4);Bang, C.(4);Fejrskov, A.(1,5);Aalykke, C.(2);Davíðsdóttir, L.(6);Rejler, M.(7);Repsilber, D.(7);Söderholm, J.D.(8);Andersen, V.(9);Høivik, M.L.(10,11);Halfvarson, J.(12);Franke, A.(4);Kjeldsen, J.(1,3);
(1)Odense University Hospital, Department of Medical Gastrointestinal Diseases S, Odense, Denmark;(2)Odense University Hospital, Internal Medicine & Emergency Department, Svendborg, Denmark;(3)University of Southern Denmark, Research Unit of Medical Gastroenterology- Department of Clinical Research, Odense, Denmark;(4)Christian-Albrechts-University of Kiel & University Medical Center Schleswig-Holstein, Institute of Clinical Molecular Biology, Kiel, Germany;(5)University Hospital of Southern Denmark- Hospital Sønderjylland, Molecular Diagnostics and Clinical Research Unit- Institute of Regional Health Research, Aabenraa, Denmark;(6)Landspitali National University Hospital of Iceland, Department of Gastroenterology, Reykjavik, Iceland;(7)Örebro University, School of Health and Medical Sciences, Örebro, Sweden;(8)Linköping University, Department of Biomedical and Clinical Sciences, Linköping, Sweden;(9)University of Southern Denmark, Institute of Regional Research, Odense, Denmark;(10)Oslo University Hospital, Department of Gastroenterology, Oslo, Norway;(11)University of Oslo, Institute of Clinical Medicine, Oslo, Norway;(12)Örebro University, Department of Gastroenterology- Faculty of Medicine and Health, Örebro, Sweden;
- Fejrskov A, Füchtbauer JD, Davíðsdóttir LG, et al. Novel biomarker profiles to improve individual diagnosis and prognosis in patients with suspected inflammatory bowel disease: protocol for the Nordic inception cohort study (NORDTREAT). BMJ Open. 2024;14(5):e083144. doi:10.1136/bmjopen-2023-083144
- Rühlemann MC, Solovjeva MEL, Zenouzi R, et al. Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida species. Gut. Published online October 25, 2019. doi:10.1136/gutjnl-2019-320008
P1337: High fat diet drives increased dysbiosis in IBD compared to healthy controlsECCO'25Year: 2025
Authors: Koentgen, S.(1)*;Zhang, F.(1);Khadka, S.(1);O'Brien, C.(2);Grimm, M.(3);Allen-Vercoe, E.(4);Hold, G.L.(1);
(1)University of New South Wales, Microbiome Research Centre, Sydney, Australia;(2)University of Canberra, Biomedical Science, Canberra, Australia;(3)University of New South Wales, St George and Sutherland Clinical School, Sydney, Australia;(4)Univarsity of Guelph, Molecular and Cellular Biology, Guelph, Canada;
1.Agans R, Gordon AH, Kramer DL, Pérez-Burillo S, Rufián-Henares JÁ, Paliy O. Dietary Fatty Acids Sustain the Growth of the Human Gut Microbiota. Applied and Environmental Microbiology. 2018;84(21). doi:10.1128/aem.01525-18
P1338: Defining the preclinical changes of microbial composition, gut barrier function, and subclinical inflammatory markers associated with future risk of ulcerative colitisECCO'25Year: 2025
Authors: Bharali, B.(1);Li, Q.(1);Xue, M.(1);Guttman, D.(2);Madsen, K.(3);Griffiths, A.(4);Panaccione, R.(5);Verdu, E.F.(6);Moayyedi, P.(6);Turpin, W.(1);Croitou, K.(1);LeeDr., S.H.(1)*;
(1)Mount Sinai Hospital- University of Toronto, Division of Gastroenterology, Toronto, Canada;(2)University of Toronto, Department of Cell & Systems Biology- and Centre for the Analysis of Genome Evolution and Function, Toronto, Canada;(3)University of Alberta, Department of Medicine, Edmonton, Canada;(4)The Hospital for Sick Kids, Division of Gastroenterology, Toronto, Canada;(5)University of Calgary, Division of Gastroenterology, Calgary, Canada;(6)McMaster University, Farncombe Family Digestive Health Research Institute, Hamilton, Canada; The GEM Project Research Consortium
Raygoza Garay JA, Turpin W, Lee S-H, et al. Gastroenterology 2023;165:670–681.
P1339: CJRB-201, a promising candidate for microbiome-based therapy with potent anti-inflammatory effects in Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Shin, C.(1)*;Park, J.(2);Lee, S.(1);Hyun, D.W.(1);Kim, D.H.(1);Jung, Y.(1);Kim, J.M.(1);Kim, J.H.(1);Baek, M.(1);Park, Y.J.(1);Lee, H.(1);Jang, H.(1);Hong, D.H.(1);Lee, J.(1);Cho, K.H.(1);Cha, I.(1);Yoo, J.A.(1);Lee, K.(3);Park, Y.R.(1);Kwon, J.E.(1);Hong, K.H.(1);Huh, J.R.(2);Chun, J.(4);
(1)CJ Bioscience, Discovery R&D, Suwon-si, Korea- Republic Of;(2)Harvard Medical School, Department of Immunology, Boston, United States;(3)CJ Bioscience, BIO Digital Platform R&D, Seoul, Korea- Republic Of;(4)CJ Bioscience, Headquarter, Seoul, Korea- Republic Of; CJ Bioscience
1. Current Biology 30, 4932–4943, 2020
2. J Antimicrob Chemother 65, 2556-2565, 2010
3. Nat Rev Immunol 14, 329–342, 2014
4. Cell Mol Gastroenterol Hepatol 1, 154-170, 2005
P1340: Gut microbiota changes are associated with type of advanced therapy in patients with Inflammatory Bowel Disease: baseline data from the Australian IBD Microbiome studyECCO'25Year: 2025
Authors: Little, R.(1,2,3)*;Jayawardana, T.(2);Zhang, F.(2);Koentgen, S.(2);Wu, N.(2);Tavakoli, P.(2);Chung, A.(2);Ho, A.(2);Read, S.(2);Boussioutas, A.(1,3);Ward, M.(1,3);Sparrow, M.(1,3);Gibson, P.(3);Ghaly, S.(4);Corte, C.(5);Talley, N.(6);Leach, S.(7);Lemberg, D.(7,8);Dutt, S.(9);Paramsothy, S.(10,11);Leong, R.(10,11);Connor, S.(12,13);Hold, G.(2);
(1)The Alfred Hospital, Department of Gastroenterology, Melbourne, Australia;(2)University of New South Wales, Microbiome Research Centre, Sydney, Australia;(3)Monash University, Faculty of Medicine- Nursing and Health Sciences, Melbourne, Australia;(4)St Vincent's Hospital, Department of Gastroenterology, Sydney, Australia;(5)University of Sydney, Faculty of Medicine, Sydney, Australia;(6)University of Newcastle, School of Medicine and Public Health, Sydney, Australia;(7)University of New South Wales, School of Women's and Children's Health, Sydney, Australia;(8)Sydney Children's Hospital, Department of Gastroenterology, Sydney, Australia;(9)The Children's Hospital at Westmead, Department of Gastroenterology, Sydney, Australia;(10)Concord Repatriation General Hospital, Department of Gastroenterology, Sydney, Australia;(11)University of Sydney, Concord Clinical School, Sydney, Australia;(12)Liverpool Hospital, Department of Gastroenterology, Sydney, Australia;(13)University of New South Wales, Faculty of Medicine and Health- South West Sydney Clinical Campuses, Sydney, Australia;
1. Little RD, Jayawardana T, Koentgen S, et al. Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions. eGastroenterology 2024;2:e100006. doi:10.1136/ egastro-2023-100006
2. Williams A, Paramsothy R, Wu N, et al. Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study. BMJ Open 2021;11:e042493. doi: 10.1136/bmjopen-2020-042493
P1341: Probing the interaction of probiotic bacterial extracellular vesicles with primary colonic epithelium using an ex-vivo organoid platformECCO'25Year: 2025
Authors: Hentschel, V.(1)*;Govindarajan , D.(1);Ziermann, A.(1);Rolle-Kampczyk, U.(2);Jehmlich, N.(2);von Bergen, M.(2);Schulte, S.(3);Schäfer, K.H.(3);Bökel, C.(4);Seufferlein, T.(1);
(1)University Clinic Ulm, Department of Internal Medicine 1, Ulm, Germany;(2)Helmholtz Centre for Environmental Research, Department of Molecular Systems Biology, Leipzig, Germany;(3)University of Applied Sciences Kaiserslautern, Campus Zweibrücken, Zweibrücken, Germany;(4)University Ulm, Core Facility for Confocal and Multiphoton Microscopy, Ulm, Germany;
P1342: Characteristics of the gut microbiota of patients with concomitant inflammatory bowel disease and psoriatic arthritisECCO'25Year: 2025
Authors: De Francisco Garcia, R.M.(1,2)*;Arboleya, S.(3);Queiro, R.(4);García-Pérez, C.(5);Gómez, E.(6);Pérez-Martínez, I.(1,2);Castaño-García, A.(1);Carballo-Folgoso, L.(1);Flórez-Díez, P.(1);Fernández-González, E.(1);Suárez, A.(1,2);González-Solares, S.(6);Gueimonde, M.(3);Riestra Menéndez, S.(1,2);
(1)Hospital Universitario Central de Asturias, Department of Gastroenterology, Oviedo, Spain;(2)Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Diet- Microbiota and Health, Oviedo, Spain;(3)Centro Superior de Investigaciones Científicas, Instituto de Productos Lácteos de Asturias, Oviedo, Spain;(4)Hospital Universitario Central de Asturias, Department of Rheumatology, Oviedo, Spain;(5)Fundación de Investigación Sanitaria de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain;(6)Universidad de Oviedo, Departamento de Biología Funcional, Oviedo, Spain;
P1343: Impact of Biologic Therapy on Gut Microbiome in Crohn's Disease: An Indian Patient Cohort StudyECCO'25Year: 2025
Authors: Raghunathan, N.(1);Gunala, N.(1);Thakur, M.(1);Mekala, D.(1);Patel, R.(1);Bharath, P.(1);Kumari, V.(1);Gavate, R.(1);Banerjee, R.(1)*;
(1)Asian Institute of Gastroenterology, IBD Centre, Hyderabad, India;
P1344: Impaired health-related quality of life is associated with alterations in gut microbiota signatures in patients with Inflammatory Bowel Disease: baseline data from the Australian IBD Microbiome studyECCO'25Year: 2025
Authors: Jayawardana, T.(1)*;Little, R.D.(1,2,3);Zhang, F.(1);Koentgen, S.(1);Wu, N.(1);Houshyar, Y.(1);Tavakoli, P.(1,4);Boussioutas, A.(2,3);Ward, M.G.(2,3);Sparrow, M.P.(2,3);Gibson, P.R.(2);Ghaly, S.(4);Corte, C.(5,6);Talley, N.J.(7,8);Leach, S.(9);Lemberg, D.(10);Dutt, S.(10,11);Paramsothy, S.(12,13);Leong, R.(12,13);Connor, S.J.(14,15,16);Hold, G.(1);
(1)University of New South Wales, Microbiome Research Centre, Sydney, Australia;(2)Monash University, Faculty of Medicine Nursing and Health Sciences, Melbourne, Australia;(3)The Alfred Hospital, Department of Gastroenterology, Melbourne, Australia;(4)St Vincent's Hospital, Department of Gastroenterology and Hepatology, Sydney, Australia;(5)University of Sydney, Faculty of Medicine, Sydney, Australia;(6)Macquaire University, Macquaire University Clinic, Sydney, Australia;(7)The University of Newcastle, School of Medicine and Public Health, Newcastle, Australia;(8)The University of Newcastle, Hunter Medical Research Institute, Newcastle, Australia;(9)University of New South Wales, Discipline of Paediatrics, Sydney, Australia;(10)Sydney Children's Hospital Randwick, Department of Gastroenterology, Sydney, Australia;(11)Sydney Children's Hospital Westmead, Department of Gastroenterology, Sydney, Australia;(12)University of Sydney, Concord Clinical School, Sydney, Australia;(13)Concord Repatriation General Hospital, Department of Gastroenterology, Sydney, Australia;(14)Western Sydney University, Ingham Institute for Applied Medical Research, Sydney, Australia;(15)Liverpool Hospital, Department of Gastroenterology and Hepatology, Sydney, Australia;(16)University of New South Wales, Faculty of Medicine and Health South West Sydney Clinical Campuses, Sydney, Australia; Australia IBD Microbiome (AIM) Study
1. Little RD, Jayawardana T, Koentgen S, et al. Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions. eGastroenterology 2024;2:e100006. doi:10.1136/ egastro-2023-100006
2. Williams A, Paramsothy R, Wu N, et al. Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study. BMJ Open 2021;11:e042493. doi: 10.1136/bmjopen-2020-042493
P1345: Association of gut microbiota changes and disease activity in patients with Crohn’s disease and ulcerative colitis: baseline data from the Australian IBD Microbiome studyECCO'25Year: 2025
Authors: Little, R.(1,2,3)*;Jayawardana, T.(3);Zhang, F.(3);Houshyar, Y.(3);Koentgen, S.(3);Wu, N.(3);Ellepola, A.(3);Tavakoli, P.(3);Chung, A.(3);Ho, A.(3);Read, S.(3);Boussioutas, A.(1,2);Ward, M.(1,2);Sparrow, M.(1,2);Gibson, P.(2);Ghaly, S.(4);Corte, C.(5);Talley, N.(6);Leach, S.(7);Lemberg, D.(7,8);Dutt, S.(9);Paramsothy, S.(10,11);Leong, R.(10,11);Connor, S.(12,13);Hold, G.(3);
(1)The Alfred Hospital, Department of Gastroenterology, Melbourne, Australia;(2)Monash University, Faculty of Medicine Nursing and Health Sciences, Melbourne, Australia;(3)University of New South Wales, Microbiome Research Centre, Sydney, Australia;(4)St Vincent's Hospital, Department of Gastroenterology, Sydney, Australia;(5)University of Sydney, Faculty of Medicine, Sydney, Australia;(6)University of Newcastle, School of Medicine and Public Health, Newcastle, Australia;(7)University of New South Wales, School of Women's and Children's Health, Sydney, Australia;(8)Sydney Children's Hospital, Department of Gastroenterology, Sydney, Australia;(9)The Children's Hospital at Westmead, Department of Gastroenterology, Sydney, Australia;(10)Concord Repatriation General Hospital, Department of Gastroenterology, Sydney, Australia;(11)University of Sydney, Concord Clinical School, Sydney, Australia;(12)Liverpool Hospital, Department of Gastroenterology, Sydney, Australia;(13)University of New South Wales, Faculty of Medicine and Health - South West Sydney Clinical Campuses, Sydney, Australia;
1. Little RD, Jayawardana T, Koentgen S, et al. Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions. eGastroenterology 2024;2:e100006. doi:10.1136/ egastro-2023-100006
2. Williams A, Paramsothy R, Wu N, et al. Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study. BMJ Open 2021;11:e042493. doi: 10.1136/bmjopen-2020-042493
P1346: Response to biologic treatment in patients with Crohn’s disease is associated with consistent decreased antibody response to bacterial flagellinsECCO'25Year: 2025
Authors: Leibovitzh, H.(1)*;Krongauz, D.(2);Schlesinger, Y.(2);Hirsch, A.(1);Ron, Y.(1);Thurm, T.(1);Godneva, A.(2);Weinberger, A.(2);Cohen, N.A.(1);Segal, E.(2);Maharshak, N.(1);
(1)Tel Aviv University- Faculty of Medicine, Tel Aviv Sourasky Medical Center- IBD Center- Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel;(2)Weizmann Institute of Science, Department of Computer Science and Applied Mathematics, Rehovot, Israel;
P1347: Gut Microbial DL-Endopeptidase in Crohn’s Disease: Links to Inflammation and Dietary ModulationECCO'25Year: 2025
Authors: Zhu , X.(1)*;Wu , X.(1);He , X.(2);Feng , R.(1);Zhou , H.(2);Chen , M.(1);
(1)Sun Yat-sen University, The First Affiliated Hospital, Guangzhou, China;(2)Southern Medical University, Zhujiang Hospital, Guangzhou, China;
P1348: Unique gut microbiome profile can distinguish Intestinal Tuberculosis and Crohn`s Disease: An Indian patient cohort studyECCO'25Year: 2025
Authors: Raghunathan, N.(1);Thakur, M.(1);Gunala, N.(1);Mekala, D.(1);Patel, R.(1);Bharath, P.(1);Banerjee, R.(1)*;
(1)Asian Institute of Gastroenterology, IBD Centre, Hyderabad, India;
P1350: The Role of oral Porphyromonas gingivalis and Its Outer Membrane Vesicles in Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Yang, C.(1)*;Zhao, Y.(2);Chen, J.(2);Chen, N.(2);
(1)Peking University People’s hospital, Department of Gastroenterology, Beijing, China;(2)Peking university people's hospital, Department of Gastroenterology, Beijing, China;
P1351: Microbiome Diversity and Taxonomic Differences in Quiescent Ulcerative Colitis: A Comparative Study of Proximal ExtensionECCO'25Year: 2025
Authors: KangMD.- PhD., S.B.(1);Jung, S.H.(2);Lee, K.M.(3)*;
(1)Daejeon St. Mary's Hospital- College of Medicine- The Catholic University of Korea, Division of Gastroenterology- Department of Internal Medicine, Daejeon, Korea- Republic Of;(2)Eunpyeong St. Mary's Hospital- College of Medicine- The Catholic University of Korea, Division of Gastroenterology- Department of Internal Medicine, Seoul, Korea- Republic Of;(3)St. Vincent's Hospital- College of Medicine- The Catholic University of Korea, Division of Gastroenterology- Department of Internal Medicine, Suwon, Korea- Republic Of;
1.Kang DY, Park JL, Yeo MK, Kang SB, Kim JM, Kim JS, Kim SY. Diagnosis of Crohn's disease and ulcerative colitis using the microbiome. BMC Microbiol. 2023 Nov 11;23(1):336. doi: 10.1186/s12866-023-03084-5.
2.Guo XY, Liu XJ, Hao JY. Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment. J Dig Dis. 2020 Mar;21(3):147-159. doi: 10.1111/1751-2980.12849.
3.Hsia K, Zhao N, Chung M et al. Alterations in the Fungal Microbiome in Ulcerative Colitis. Inflamm Bowel Dis. 2023 Oct 3;29(10):1613-1621. doi: 10.1093/ibd/izad082.
4.Fang J, Wang H, Zhou Y el al. Slimy partners: the mucus barrier and gut microbiome in ulcerative colitis. Exp Mol Med. 2021 May;53(5):772-787.
5.Bullard BM, VanderVeen BN, McDonald SJ, Cardaci TD, Murphy EA. Cross talk between the gut microbiome and host immune response in ulcerative colitis: nonpharmacological strategies to improve homeostasis. Am J Physiol Gastrointest Liver Physiol. 2022 Dec 1;323(6):G554-G561. doi: 10.1152/ajpgi.00210.2022.
6.Basha OM, Hafez RA, Salem SM, Anis RH, Hanafy AS. Impact of gut Microbiome alteration in Ulcerative Colitis patients on disease severity and outcome. Clin Exp Med. 2023 Sep;23(5):1763-1772. doi: 10.1007/s10238-022-00917-x.
7.Roda G, Narula N, Pinotti R et al. Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis. Aliment Pharmacol Ther. 2017 Jun;45(12):1481-1492. doi: 10.1111/apt.14063.
P1352: Segmental Mucosal Microbiome Variations Across Different Inflammation Extents in Ulcerative ColitisECCO'25Year: 2025
Authors: Shin, J.(1)*;Song, J.H.(2);Cha, B.(3);Hong, J.T.(3);Kwon, K.S.(3);kim, J.S.(4);
(1)Inha university hospital, Internal Medicine gastroenterology and hepatology, Incheon, Korea- Republic Of;(2)Konkuk University Medical Center, Department of internal Medicine, Seoul, Korea- Republic Of;(3)Inha University Hospital, Department of internal Medicine, Incheon, Korea- Republic Of;(4)Incheon National University, Department of Nano-Bioengineering, Incheon, Korea- Republic Of;
1. Ko CW, Singh S, Feuerstein JD, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology 2019;156:748-764.
2. Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis 2022;16:2-17.
3. Akyüz, Filiz, et al. "Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition." Intestinal Research (2024).
4. Pei, Ling-yan, et al. "Role of colonic microbiota in the pathogenesis of ulcerative colitis." BMC gastroenterology 19 (2019): 1-11.
5. Nishihara, Yuichiro, et al. "Mucosa-associated gut microbiota reflects clinical course of ulcerative colitis." Scientific reports 11.1 (2021): 13743.
